A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer - Clinical Trial NCTNCT05125016
Business Opportunities for NCT05125016
Connect with principal investigators, study coordinators, and key decision makers for this PHASE1, PHASE2 trial studying investigational therapy for Metastatic Castration-resistant Prostate Cancer.
Clinical Trial Information
- Study Sponsor
- Sponsor information available
- Drug/Intervention
- Study intervention details available
- Therapeutic Area
- Prostatic Neoplasms
- Study Phase
- PHASE1, PHASE2
- Study Status
- RECRUITING
- NCT Number
- NCTNCT05125016
Find Contact Information
Access exclusive contact details for:
- Principal investigators and sub-investigators
- Study coordinators and research staff
- Site directors and facility contacts
- Sponsor representatives and CRO partners
- Business development professionals
- Clinical operations managers
Clinical Trial Locations
This study has 13 locations across United States.
Study Site
Palo Alto, California United States
Study Site
Louisville, Kentucky United States
Study Site
Baltimore, Maryland United States
Study Site
New Brunswick, New Jersey United States
Study Site
Buffalo, New York United States
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships